US FDA orders fluoroquinolone labeling change to strengthen nerve damage warning
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has ordered the makers of oral and injectable fluoroquinolones to revise the labeling and medication guides for their products to strengthen the warnings about potentially permanent serious nerve damage, known as peripheral neuropathy, which may occur soon after the drugs are used1.